Literature DB >> 35212928

MicroRNAs and drug resistance in colorectal cancer with special focus on 5-fluorouracil.

Fahima Danesh Pouya1, Maria Gazouli2, Yousef Rasmi3,4, Dimitra Ioanna Lampropoulou5, Mohadeseh Nemati1.   

Abstract

Colorectal cancer is globally one of the most common cancers in all age groups. The current chemotherapy combinations for colorectal cancer treatment include 5-fluorouracil-based regimens; however, drug resistance remains one of the main reasons for chemotherapy failure and disease recurrence. Many studies have determined colorectal cancer chemoresistance mechanisms such as drug efflux, cell cycle arrest, DNA damage repair, apoptosis, autophagy, vital enzymes, epigenetic, epithelial-mesenchymal transition, stem cells, and immune system suppression. Several microRNAs affect drug resistance by regulating the drug resistance-related target genes in colorectal cancer. These drug resistance-related miRNAs may be used as promising biomarkers for predicting drug response or as potential therapeutic targets for treating patients with colorectal cancer. This work reviews and discuss the role of selected microRNAs in 5-fluorouracil resistance and their molecular mechanisms in colorectal cancer.
© 2022. The Author(s), under exclusive licence to Springer Nature B.V.

Entities:  

Keywords:  5-fluorouracil; Colorectal cancer; Drug resistance; MicroRNA

Mesh:

Substances:

Year:  2022        PMID: 35212928     DOI: 10.1007/s11033-022-07227-1

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.742


  116 in total

Review 1.  miRNAs, cancer, and stem cell division.

Authors:  Carlo M Croce; George A Calin
Journal:  Cell       Date:  2005-07-15       Impact factor: 41.582

2.  Global cancer statistics, 2002.

Authors:  D Max Parkin; Freddie Bray; J Ferlay; Paola Pisani
Journal:  CA Cancer J Clin       Date:  2005 Mar-Apr       Impact factor: 508.702

3.  Global cancer statistics.

Authors:  Ahmedin Jemal; Freddie Bray; Melissa M Center; Jacques Ferlay; Elizabeth Ward; David Forman
Journal:  CA Cancer J Clin       Date:  2011-02-04       Impact factor: 508.702

4.  MicroRNA-10b is a prognostic indicator in colorectal cancer and confers resistance to the chemotherapeutic agent 5-fluorouracil in colorectal cancer cells.

Authors:  Naohiro Nishida; Shinya Yamashita; Koshi Mimori; Tomoya Sudo; Fumiaki Tanaka; Kohei Shibata; Hirofumi Yamamoto; Hideshi Ishii; Yuichiro Doki; Masaki Mori
Journal:  Ann Surg Oncol       Date:  2012-02-10       Impact factor: 5.344

Review 5.  Emerging Systemic Therapies for Colorectal Cancer.

Authors:  Christine M Veenstra; John C Krauss
Journal:  Clin Colon Rectal Surg       Date:  2018-04-01

6.  A thymidylate synthase ternary complex-specific antibody, FTS, permits functional monitoring of fluoropyrimidines dosing.

Authors:  Kalpesh Patel; Sashidhar R Yerram; Nilofer A Azad; Scott E Kern
Journal:  Oncotarget       Date:  2012-07

Review 7.  MicroRNAs in apoptosis, autophagy and necroptosis.

Authors:  Zhenyi Su; Zuozhang Yang; Yongqing Xu; Yongbin Chen; Qiang Yu
Journal:  Oncotarget       Date:  2015-04-20

Review 8.  Epidemiology of colorectal cancer: incidence, mortality, survival, and risk factors.

Authors:  Prashanth Rawla; Tagore Sunkara; Adam Barsouk
Journal:  Prz Gastroenterol       Date:  2019-01-06

9.  5-FU therapeutic drug monitoring as a valuable option to reduce toxicity in patients with gastrointestinal cancer.

Authors:  Katarzyna Morawska; Françoise Goirand; Laurine Marceau; Madeline Devaux; Adèle Cueff; Aurélie Bertaut; Julie Vincent; Leila Bengrine-Lefevre; François Ghiringhelli; Antonin Schmitt
Journal:  Oncotarget       Date:  2018-01-30

Review 10.  5-Fluorouracil resistance mechanisms in colorectal cancer: From classical pathways to promising processes.

Authors:  Sabrina Blondy; Valentin David; Mireille Verdier; Muriel Mathonnet; Aurélie Perraud; Niki Christou
Journal:  Cancer Sci       Date:  2020-08-13       Impact factor: 6.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.